Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Prostate Cancer treatment details. Chemotherapy. Dana Farber Cancer Institute, Boston, Massachusetts , United States

Survival: 19.0 months
Toxicity Grade: 4
Treatments: Chemotherapy
Drugs: Emcyt
Country: United States
City/State/Province: Boston, Massachusetts
Hospital: Dana Farber Cancer Institute
Journal: Link
Date: 12/2003

Patients: This Phase II study involved 40 patients with hormone refractory prostate cancer. Median age was 68 years. The median years since diagnosis was 6 years. Thirty-five patients had bone metastasis.

Treatment: The treatment consisted of three chemotherapy drugs estramustine (emcyt), docetaxel (taxotere), and carboplatin (paraplatin).

Toxicity: Grade 4 toxicities included neutrophils, cardiac ischemia/infarction, thrombotic microangiopathy, dehydration, diarrhea without colostomy, aldnine transaminase, hypocalcemia, and hyperglycemia.

Results: The median survival was 19 months.

Support: Partial support came from Aventis Pharmaceuticals, Inc. In addition, one of the authors has served on advisory boards to Aventis and Bristol-Myers Squibb and another has served on the Speakers Bureau for Aventis and Amgen and has received research support from Aventis. Bristol-Myers Squibb markets or manufactures paraplatin and Aventis Pharmaceutical markets or manufactures taxotere.

Correspondence: William K. Oh, MD

E-mail to a Friend Email Physician More Information